ACTG 219--PEDIATRIC HIV LATE OUTCOMES PROTOCOL

ACTG 219--儿科艾滋病毒晚期结果方案

• 批准号: 6114937
• 负责人: ELIZABETH G MCFARLAND
• 金额: $ 1.99万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6114937
• 关键词: AIDS therapy; AIDS vaccines; adolescence (12-20); antiAIDS agent; child (0-11); clinical research; drug adverse effect; human subject; human therapy evaluation; infant human (0-1 year); longitudinal human study; outcomes research; pediatric AIDS; quality of life

This longitudinal study will follow infants, children and adolescents enrolled in perinatal and pediatric ACTG clinical trials in order to monitor late consequences of therapy including long-term survival and quality of life; benefits, toxicities or other adverse outcomes form use of antiretroviral, immune and vaccine-based therapies geared to both prevent the progression of HIV and prolong the survival of HIV-infected individuals.

这项纵向研究将跟踪参加围产期和儿科 ACTG 临床试验的婴儿、儿童和青少年，以监测治疗的后期后果，包括长期生存和生活质量；使用抗逆转录病毒、免疫和疫苗疗法可以预防艾滋病毒的进展并延长艾滋病毒感染者的生存期，从而产生益处、毒性或其他不良后果。